Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer.
Publication/Presentation Date
9-1-2007
Abstract
PURPOSE: This study evaluated the strategy of performing neck dissection (ND) without primary tumor resection prior to definitive chemoradiotherapy (CRT) for N2+ oropharynx cancer.
METHODS: We analyzed records of 25 patients who underwent ND before concurrent CRT with weekly low-dose concurrent paclitaxel and a platinum compound. The extent of ND was highly customized (1 to 39 nodes) and median radiotherapy dose was 70 Gy.
RESULTS: Median follow-up was 36 months. Two-year and 3-year actuarial locoregional control rates were 95% and 88%. No patient had regional neck nodal failure. Two-year rate of freedom from distant metastases was 91%. The 2- and 3-year event-free survival rates were 88% and 75%. Fifteen percent had Grade 3+ late toxicity; none had permanent gastrostomy tube dependence.
CONCLUSIONS: Neck dissection without primary tumor resection before definitive chemoradiotherapy for oropharynx cancer is a safe and effective management program and warrants further exploration.
Volume
137
Issue
3
First Page
416
Last Page
421
ISSN
0194-5998
Published In/Presented At
Cupino, A., Axelrod, R., Anne, P. R., Sidhu, K., Lavarino, J., Kung, B., Rosen, M., Keane, W., & Machtay, M. (2007). Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 137(3), 416–421. https://doi.org/10.1016/j.otohns.2007.03.021
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
17765768
Department(s)
Administration and Leadership
Document Type
Article